Welcome to our dedicated page for Abbott Labs news (Ticker: ABT), a resource for investors and traders seeking the latest updates and insights on Abbott Labs stock.
Abbott Laboratories (NYSE: ABT) generates a steady flow of news across diagnostics, medical devices, nutritionals and branded generic medicines, reflecting its role as a global healthcare company serving people in more than 160 countries. News coverage on this page highlights regulatory milestones, product launches, clinical data, corporate actions and community initiatives that shape Abbott’s business and its impact on patients.
Recent announcements include FDA approvals and clearances for cardiovascular and structural heart technologies, such as the Volt PFA System for treating atrial fibrillation and the Amplatzer Piccolo Delivery System for minimally invasive closure of patent ductus arteriosus in premature infants. Abbott also reports developments in diabetes care and metabolic health, including enhancements to its Libre app through the Libre Assist feature, which uses generative AI and continuous glucose monitoring data to help people living with diabetes understand how food choices may affect glucose levels, and the expansion of its Lingo over-the-counter continuous glucose monitor to additional mobile platforms.
Investors and observers will also find news about Abbott’s nutrition business, such as new Ensure Max Protein shakes aimed at supporting muscle health for active and older adults, as well as information on public health partnerships and community programs like the "We Give Blood" competition with the Big Ten Conference and the HeartMates community for people with heart health challenges. Corporate updates include dividend declarations and increases, as well as the announced Agreement and Plan of Merger to acquire Exact Sciences Corporation, which would expand Abbott’s presence in cancer screening and precision oncology diagnostics.
This news feed provides a centralized view of Abbott’s latest announcements, allowing readers to follow developments in its key business segments and understand how new products, regulatory events and strategic transactions may influence the company over time.
Abbott has received FDA approval for its Eterna spinal cord stimulation (SCS) system, designed to treat chronic pain. This device is the smallest rechargeable spinal cord stimulator on the market, requiring as few as five recharges annually, significantly optimizing patient comfort. Eterna employs Abbott's BurstDR stimulation technology, which has been clinically proven to alleviate pain more effectively than traditional methods. With over 50 million Americans affected by chronic pain, Abbott aims to enhance healthcare delivery and improve patient outcomes through innovative solutions.
Abbott (NYSE: ABT) and the Brain Injury Association of America have co-founded Concussion Awareness Now, a coalition of nearly 20 advocacy groups aimed at increasing awareness about concussions. The initiative emphasizes the importance of diagnosis and treatment, with over half of individuals suspecting a concussion neglecting to seek care. Actress Rebel Wilson, who recently experienced a concussion, shares her story to support the cause. The coalition aims to change societal perceptions surrounding concussions and encourage proper medical attention.
Abbott (NYSE: ABT) announced an 8.5% increase in its quarterly dividend, raising it to 51 cents per share. This marks the company’s 51st consecutive year of dividend growth and the 396th consecutive quarterly dividend, to be paid on Feb. 15, 2023, to shareholders of record by Jan. 13, 2023. Abbott is recognized in the S&P 500 Dividend Aristocrats Index for consistent annual dividend increases over at least 25 years, reflecting its commitment to sustainable growth and shareholder returns.
Abbott (NYSE: ABT) has won three CES 2023 Innovation Awards from the Consumer Technology Association for its innovative health technologies. The awarded products include the Aveir VR Leadless Pacemaker, the Proclaim Plus SCS System, and the Alinity m Monkeypox PCR test. Abbott's achievements continue as the company was previously recognized for its FreeStyle Libre technology, named the best medical technology of the last 50 years by the Galien Foundation. This recognition underscores Abbott's commitment to advancing healthcare solutions globally.
Surmodics announced positive results from the 24-month follow-up of its TRANSCEND clinical trial at the VIVA conference in Las Vegas. The study involved 446 patients and compared the SurVeil DCB with the leading IN.PACT Admiral DCB. Results show that SurVeil achieved a primary patency rate of 70.8% versus 70.4% for IN.PACT, with comparable safety profiles. SurVeil uses a significantly lower dose of paclitaxel, which may enhance patient outcomes. Surmodics holds a partnership with Abbott (ABT) for commercialization upon FDA approval.
Summary not available.
Surmodics, Inc. (NASDAQ:SRDX) announced that findings from the TRANSCEND clinical trial will be shared at the Vascular InterVentional Advances (VIVA) conference on November 1, 2022. Dr. Kenneth Rosenfield will present 24-month data on the efficacy and safety of the SurVeil drug-coated balloon (DCB) compared to IN.PACT Admiral DCB. Initial results at 12 months indicated non-inferiority for SurVeil with a lower drug dose. Surmodics has an agreement with Abbott (NYSE: ABT) for commercialization rights.
Abbott's third-quarter sales reached $10.4 billion with a 4.7% decline on a reported basis but a 1.3% increase organically. GAAP EPS was $0.81, while adjusted EPS surged to $1.15. Abbott raised its full-year 2022 EPS guidance to $3.75-$3.81 (GAAP) and $5.17-$5.23 (adjusted). Strong growth was noted in U.S. Medical Devices, particularly in Electrophysiology, Structural Heart, and Diabetes Care. The launch of FreeStyle Libre 3 boosted sales, despite declines in Nutrition and Diagnostics due to past manufacturing issues and diminished COVID-19 testing revenue.
Abbott (NYSE: ABT) has partnered with The Home Edit to redesign medicine cabinets in preparation for the flu and virus season, which is impacted by COVID-19. The initiative focuses on organizing health essentials like the BinaxNOW COVID-19 Antigen Self Test, enhancing family preparedness. With over a billion BinaxNOW tests produced, Abbott emphasizes the importance of at-home testing for quick results. The Home Edit offers organizational tips to help families maintain essential items efficiently and visually appeal to their health space.
A recent study published in The New England Journal of Medicine demonstrates that Abbott's FreeStyle Libre 2 glucose monitoring system significantly lowers glycated hemoglobin (HbA1c) levels in adults with Type 1 diabetes compared to self-monitoring of blood glucose (SMBG). At the end of the 24-week study, FreeStyle Libre users exhibited a 0.5% reduction in HbA1c, while SMBG users only saw a 0.2% decrease. The study also noted improvements in quality of life and greater treatment satisfaction among FreeStyle Libre users.